Abstract
Background/Aims: Soluble guanylate cyclase (sGC) exists as reduced, oxidized, and heme-free forms. Currently, it is unclear whether endovascular mechanical stenosis has an impact on vascular tone control by drugs targeting sGC, namely cGMP generators. Methods: Pharmacological responses to acidified sodium nitrite (reduced sGC stimulant) and BAY 60-2770 (oxidized/heme-free sGC stimulant) were studied in balloon-injured rat carotid arteries at several time points. In addition, sGC expression was detected by immunohistochemistry. Results: At 1 day after injury, acidified sodium nitrite-induced relaxation was attenuated in the injured artery, whereas BAY 60-2770-induced relaxation was augmented. Similar attenuation of response to acidified sodium nitrite was seen at 7 and 14 days after injury. On the other hand, the augmentation of response to BAY 60-2770 disappeared at 7 and 14 days after injury. At 1 day after injury, the immunohistochemical expression pattern of sGC in the smooth muscle layer of the injured artery was not different from that of the uninjured artery. However, in the injured artery, the intensity of sGC staining was weak at 7 and 14 days after injury. Conclusion: Balloon injury alters vascular responsiveness to cGMP generators, which seems to be associated with the form and/or expression of sGC.
References
1.
Kraehling
JR
, Sessa
WC
. Contemporary approaches to modulating the nitric oxide-cGMP pathway in cardiovascular disease
. Circ Res
. 2017
Mar
;120
(7
):1174
–82
.
[PubMed]
0009-73302.
Follmann
M
, Griebenow
N
, Hahn
MG
, Hartung
I
, Mais
FJ
, Mittendorf
J
, et al. The chemistry and biology of soluble guanylate cyclase stimulators and activators
. Angew Chem Int Ed Engl
. 2013
Sep
;52
(36
):9442
–62
.
[PubMed]
0570-08333.
Shah
RC
, Sanker
S
, Wood
KC
, Durgin
BG
, Straub
AC
. Redox regulation of soluble guanylyl cyclase
. Nitric Oxide
. 2018
Jun
;76
:97
–104
.
[PubMed]
1089-86034.
Mónica
FZ
, Antunes
E
. Stimulators and activators of soluble guanylate cyclase for urogenital disorders
. Nat Rev Urol
. 2018
Jan
;15
(1
):42
–54
.
[PubMed]
1759-48125.
Furchgott
RF
. Studies on relaxation of rabbit aorta by sodium nitrite: the basis for the proposal that the acid-activatable inhibitory factor from bovine retractor penis is inorganic nitrite and the endothelium-derived relaxing factor is nitric oxide. In: Vanhoutte
PM
, editor. Vasodilation: Vascular Smooth Muscle, Peptides, Autonomic Nerves, and Endothelium
. New York
: Raven Press
; 1988
. pp. 401
–14
.6.
Knorr
A
, Hirth-Dietrich
C
, Alonso-Alija
C
, Härter
M
, Hahn
M
, Keim
Y
, et al. Nitric oxide-independent activation of soluble guanylate cyclase by BAY 60-2770 in experimental liver fibrosis
. Arzneimittelforschung
. 2008
;58
(2
):71
–80
.
[PubMed]
0004-41727.
Tawa
M
, Shimosato
T
, Iwasaki
H
, Imamura
T
, Okamura
T
. Different influences of extracellular and intracellular superoxide on relaxation through the NO/sGC/cGMP pathway in isolated rat iliac arteries
. J Cardiovasc Pharmacol
. 2015
Feb
;65
(2
):160
–7
.
[PubMed]
1533-40238.
Juni
RP
, Duckers
HJ
, Vanhoutte
PM
, Virmani
R
, Moens
AL
. Oxidative stress and pathological changes after coronary artery interventions
. J Am Coll Cardiol
. 2013
Apr
;61
(14
):1471
–81
.
[PubMed]
0735-10979.
Chen
C
, Hu
JT
, Tu
YJ
, Wu
JC
, Liang
J
, Gao
LL
, et al. Effects of isosorbide mononitrate on the restoration of injured artery in mice in vivo
. Eur J Pharmacol
. 2010
Aug
;640
(1-3
):150
–6
.
[PubMed]
0014-299910.
Lippolis
L
, Sorrentino
R
, Popolo
A
, Maffia
P
, Nasti
C
, d’Emmanuele di Villa Bianca
R
, et al. Time course of vascular reactivity to contracting and relaxing agents after endothelial denudation by balloon angioplasty in rat carotid artery
. Atherosclerosis
. 2003
Dec
;171
(2
):171
–9
.
[PubMed]
0021-915011.
Tawa
M
, Okamura
T
. Soluble guanylate cyclase redox state under oxidative stress conditions in isolated monkey coronary arteries
. Pharmacol Res Perspect
. 2016
Sep
;4
(5
):e00261
.
[PubMed]
2052-170712.
Kukovetz
WR
, Holzmann
S
, Wurm
A
, Pöch
G
. Evidence for cyclic GMP-mediated relaxant effects of nitro-compounds in coronary smooth muscle
. Naunyn Schmiedebergs Arch Pharmacol
. 1979
Dec
;310
(2
):129
–38
.
[PubMed]
0028-129813.
Meurer
S
, Pioch
S
, Pabst
T
, Opitz
N
, Schmidt
PM
, Beckhaus
T
, et al. Nitric oxide-independent vasodilator rescues heme-oxidized soluble guanylate cyclase from proteasomal degradation
. Circ Res
. 2009
Jul
;105
(1
):33
–41
.
[PubMed]
0009-733014.
Sinnaeve
P
, Chiche
JD
, Nong
Z
, Varenne
O
, Van Pelt
N
, Gillijns
H
, et al. Soluble guanylate cyclase alpha(1) and beta(1) gene transfer increases NO responsiveness and reduces neointima formation after balloon injury in rats via antiproliferative and antimigratory effects
. Circ Res
. 2001
Jan
;88
(1
):103
–9
.
[PubMed]
0009-733015.
Hirschberg
K
, Tarcea
V
, Páli
S
, Barnucz
E
, Gwanmesia
PN
, Korkmaz
S
, et al. Cinaciguat prevents neointima formation after arterial injury by decreasing vascular smooth muscle cell migration and proliferation
. Int J Cardiol
. 2013
Jul
;167
(2
):470
–7
.
[PubMed]
0167-527316.
Chen
L
, Daum
G
, Fischer
JW
, Hawkins
S
, Bochaton-Piallat
ML
, Gabbiani
G
, et al. Loss of expression of the beta subunit of soluble guanylyl cyclase prevents nitric oxide-mediated inhibition of DNA synthesis in smooth muscle cells of old rats
. Circ Res
. 2000
Mar
;86
(5
):520
–5
.
[PubMed]
0009-733017.
Melichar
VO
, Behr-Roussel
D
, Zabel
U
, Uttenthal
LO
, Rodrigo
J
, Rupin
A
, et al. Reduced cGMP signaling associated with neointimal proliferation and vascular dysfunction in late-stage atherosclerosis
. Proc Natl Acad Sci USA
. 2004
Nov
;101
(47
):16671
–6
.
[PubMed]
0027-842418.
Jabs
A
, Oelze
M
, Mikhed
Y
, Stamm
P
, Kröller-Schön
S
, Welschof
P
, et al. Effect of soluble guanylyl cyclase activator and stimulator therapy on nitroglycerin-induced nitrate tolerance in rats
. Vascul Pharmacol
. 2015
Aug
;71
:181
–91
.
[PubMed]
1537-189119.
Qin
ZX
, Yu
P
, Qian
DH
, Song
MB
, Tan
H
, Yu
Y
, et al. Hydrogen-rich saline prevents neointima formation after carotid balloon injury by suppressing ROS and the TNF-α/NF-κB pathway
. Atherosclerosis
. 2012
Feb
;220
(2
):343
–50
.
[PubMed]
0021-915020.
Murakami
S
, Sakurai
T
, Toda
Y
, Morito
A
, Sakono
M
, Fukuda
N
. Prevention of neointima formation by taurine ingestion after carotid balloon injury
. Vascul Pharmacol
. 2010
Sep-Oct
;53
(3-4
):177
–84
.
[PubMed]
1537-189121.
Jagadeesha
DK
, Miller
FJ
Jr, Bhalla
RC
. Inhibition of apoptotic signaling and neointimal hyperplasia by tempol and nitric oxide synthase following vascular injury
. J Vasc Res
. 2009
;46
(2
):109
–18
.
[PubMed]
1018-117222.
Holt
AW
, Martin
DN
, Shaver
PR
, Adderley
SP
, Stone
JD
, Joshi
CN
, et al. Soluble guanylyl cyclase-activated cyclic GMP-dependent protein kinase inhibits arterial smooth muscle cell migration independent of VASP-serine 239 phosphorylation
. Cell Signal
. 2016
Sep
;28
(9
):1364
–79
.
[PubMed]
0898-656823.
Mönks
D
, Lange
V
, Silber
RE
, Markert
T
, Walter
U
, Nehls
V
. Expression of cGMP-dependent protein kinase I and its substrate VASP in neointimal cells of the injured rat carotid artery
. Eur J Clin Invest
. 1998
May
;28
(5
):416
–23
.
[PubMed]
0014-297224.
Yahagi
K
, Kolodgie
FD
, Otsuka
F
, Finn
AV
, Davis
HR
, Joner
M
, et al. Pathophysiology of native coronary, vein graft, and in-stent atherosclerosis
. Nat Rev Cardiol
. 2016
Feb
;13
(2
):79
–98
.
[PubMed]
1759-500225.
Stasch
JP
, Schmidt
PM
, Nedvetsky
PI
, Nedvetskaya
TY
, H S
AK
, Meurer
S
, et al. Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels
. J Clin Invest
. 2006
Sep
;116
(9
):2552
–61
.
[PubMed]
0021-973826.
Laber
U
, Kober
T
, Schmitz
V
, Schrammel
A
, Meyer
W
, Mayer
B
, et al. Effect of hypercholesterolemia on expression and function of vascular soluble guanylyl cyclase
. Circulation
. 2002
Feb
;105
(7
):855
–60
.
[PubMed]
0009-732227.
Zhou
X
, Zhang
J
, Feng
G
, Shen
J
, Kong
D
, Zhao
Q
. Nitric oxide-releasing biomaterials for biomedical applications
. Curr Med Chem
. 2016
;23
(24
):2579
–601
.
[PubMed]
0929-8673© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
